The Oklahoma Medical Research Foundation proposes a Specialized Center of Research (SCOR) in systemic lupus erythematosus which will focus on understanding the roles of autoantibodies in SLE. The overarching goal of this center will be to integrate clinical rheumatic disease research with basic science investigators from throughout campus thereby strengthening basic science and patient oriented research in this state. Dr. Morris Reichlin is the Director, and he brings a distinguished career's worth of rheumatic disease research activities to this new integrated program. Briefly, this SCOR has five key investigators, five collaborating investigators (in-state), five collaborating investigators (out-of-state), nine additional arthritis investigators, fourteen basic science investigators, a Data and Analysis Core Director, Advisory Committee and a host of adjunct faculty, post-doctoral fellows, clinical fellows, MD-PhD students and graduate students. The key projects for this proposal include various approaches to understand how autoimmune responses start in SLE and how autoantibodies could lead to pathogenesis. The major projects in this SCOR will focus on understanding the development of autoantibodies with regards to symptom and SLE disease onset, exploring the role of autoantibodies in the development of dyslipidemias and accelerated cardiac disease, evaluating the basic role of B cell tolerance in the accrual of lupus autoantibodies, identifying potential etiologic triggers of these aberrant autoimmune responses and assessing the genetic predisposition to a severe serological and clinical SLE phenotype. A Data and Analysis Core and Administrative Core will support each of these individual projects. The primary Oklahoma SLE SCOR objectives are fourfold. First, this SCOR will strengthen research through integration of basic and clinical science in finding key etiological factors for SLE by supporting the above mentioned research projects. Second, biostatistical/research design issues will be incorporated into all ongoing rheumatic disease research in order to raise the current level of research activity. Third, key unique patient resources will be shared by several of the projects. Finally, this SCOR will provide a multidisciplinary structure and resources to strengthen current clinical rheumatic disease research through the influence of strong basic scientists involved in cardiovascular biology, lupus genetics, inflammation, coagulation, molecular biology, immunobiology, immunogenetics, clinical pharmacology and protein studies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Specialized Center (P50)
Project #
5P50AR048940-05
Application #
7125194
Study Section
Special Emphasis Panel (ZAR1-TLB-B (M1))
Program Officer
Serrate-Sztein, Susana
Project Start
2002-09-05
Project End
2009-08-31
Budget Start
2006-09-01
Budget End
2009-08-31
Support Year
5
Fiscal Year
2006
Total Cost
$1,155,000
Indirect Cost
Name
Oklahoma Medical Research Foundation
Department
Type
DUNS #
077333797
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Liu, Ke; Kurien, Biji T; Zimmerman, Sarah L et al. (2016) X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome. Arthritis Rheumatol 68:1290-1300
Lu, Xiaoming; Zoller, Erin E; Weirauch, Matthew T et al. (2015) Lupus Risk Variant Increases pSTAT1 Binding and Decreases ETS1 Expression. Am J Hum Genet 96:731-9
Kottyan, Leah C; Zoller, Erin E; Bene, Jessica et al. (2015) The IRF5-TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. Hum Mol Genet 24:582-96
Morris, D L; Fernando, M M A; Taylor, K E et al. (2014) MHC associations with clinical and autoantibody manifestations in European SLE. Genes Immun 15:210-7
Molineros, Julio E; Maiti, Amit K; Sun, Celi et al. (2013) Admixture mapping in lupus identifies multiple functional variants within IFIH1 associated with apoptosis, inflammation, and autoantibody production. PLoS Genet 9:e1003222
Dozmorov, Igor; Dominguez, Nicolas; Sestak, Andrea L et al. (2013) Evidence of dynamically dysregulated gene expression pathways in hyperresponsive B cells from African American lupus patients. PLoS One 8:e71397
Vaughn, Samuel E; Kottyan, Leah C; Munroe, Melissa E et al. (2012) Genetic susceptibility to lupus: the biological basis of genetic risk found in B cell signaling pathways. J Leukoc Biol 92:577-91
Hughes, Travis; Adler, Adam; Merrill, Joan T et al. (2012) Analysis of autosomal genes reveals gene-sex interactions and higher total genetic risk in men with systemic lupus erythematosus. Ann Rheum Dis 71:694-9
Castillejo-López, Casimiro; Delgado-Vega, Angélica M; Wojcik, Jerome et al. (2012) Genetic and physical interaction of the B-cell systemic lupus erythematosus-associated genes BANK1 and BLK. Ann Rheum Dis 71:136-42
Ko, Kichul; Franek, Beverly S; Marion, Miranda et al. (2012) Genetic ancestry, serum interferon-? activity, and autoantibodies in systemic lupus erythematosus. J Rheumatol 39:1238-40

Showing the most recent 10 out of 100 publications